bioRxiv · 10.1101/2021.01.15.426463
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
Abstract
Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Watanabe, Y., Mendonca, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F., Davies, H., Ulaszewska, M., Belij-Rammerstorfer, S., Morris, S., Krebs, A.-S., Dejnirattisai, W., Mongkolsapaya, J., Supasa, P., Screaton, G. R., Green, C. M., Lambe, T., Zhang, P., Gilbert, S. C., Crispin, M.. 2021-01-19. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. https://doi.org/10.1101/2021.01.15.426463
Cite the original work for its findings. Save a collection to share your selection of sources.